Contents of this document
Earnings presentation materialsFirst quarter of the fiscal year ended March 20265 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥85 million
Operating profit¥-196 million
Ordinary income¥-199 million
Net income¥-200 million
Selling, general and administrative expenses¥227 million
Gross Profit Margin35.3%、前年同期比の増減ポイントはNot disclosed
Operating profit margin-230.6%、前年同期比の増減ポイントはNot disclosed
Results for the three months of the current quarter2026年3月期第1四半期として、売上高85百万円、営業損失196百万円、経常損失199百万円、親会社株主に帰属する当期純損失200百万円
Full-year earnings forecast
Net Sales
¥590 million
Operating loss
¥-895 million
Ordinary loss
¥-883 million
Net loss attributable to owners of the parent
¥-889 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progressing broadly in line with the planBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in CDMO business sales¥85 million
- Increase in R&D expenditure¥18 million
- Higher other SG&A expenses¥13 million
- 円高進行による有価証券評価損・為替差損¥5 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
主にCDMO事業の売上増加を予想。米国での治験開始に向けた前臨床試験費用（スタンフォード大学と協業）の増加により赤字は拡大予想。数値前提はNot disclosedNew initiatives
- 再生CDMO補助金の新技術導入促進枠への採択
- 補助金を活用した設備投資・高度人材育成
- 中之島クロスへの設備投資
- スタンフォード大学との共同研究開始
- 朝日インテックとの共同研究開発
- 大阪・関西万博への展示物の開発・提供
Financial targets
自己資本比率94.1％、現預金比率84.3％の実績値は記載されているが、財務目標はNot disclosed| Item | Details |
|---|---|
| Document type | Earnings presentation materials |
| Fiscal Period Covered | First quarter of the fiscal year ended March 2026 |
| Net Sales | ¥85 million |
| Operating profit | ¥-196 million |
| Ordinary income | ¥-199 million |
| Net income | ¥-200 million |
| Gross Profit Margin | 35.3%、前年同期比の増減ポイントはNot disclosed |
| Operating profit margin | -230.6%、前年同期比の増減ポイントはNot disclosed |
| Selling, general and administrative expenses | ¥227 million |
| Results for the three months of the current quarter | 2026年3月期第1四半期として、売上高85百万円、営業損失196百万円、経常損失199百万円、親会社株主に帰属する当期純損失200百万円 |
| Full-year earnings forecast | Net Sales ¥590 million / Operating loss ¥-895 million / Ordinary loss ¥-883 million / Net loss attributable to owners of the parent ¥-889 million |
| Self-assessment against the plan | Progressing broadly in line with the plan |
| Breakdown of Factors Affecting the Change | Factors Increase in CDMO business sales / Amount ¥85 million, Factors Increase in R&D expenditure / Amount ¥18 million, Factors Higher other SG&A expenses / Amount ¥13 million, Factors 円高進行による有価証券評価損・為替差損 / Amount ¥5 million |
| Assumptions Underlying the Business Outlook | 主にCDMO事業の売上増加を予想。米国での治験開始に向けた前臨床試験費用（スタンフォード大学と協業）の増加により赤字は拡大予想。数値前提はNot disclosed |
| Financial targets | 自己資本比率94.1％、現預金比率84.3％の実績値は記載されているが、財務目標はNot disclosed |
| New initiatives | 再生CDMO補助金の新技術導入促進枠への採択, 補助金を活用した設備投資・高度人材育成, 中之島クロスへの設備投資, スタンフォード大学との共同研究開始, 朝日インテックとの共同研究開発, 大阪・関西万博への展示物の開発・提供 |
Items this document does not state (15)
Progress against full-year forecastSegment resultsKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.